Back to Search
Start Over
Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab).
- Source :
-
Clinical and experimental dermatology [Clin Exp Dermatol] 2003 Jul; Vol. 28 (4), pp. 366-8. - Publication Year :
- 2003
-
Abstract
- We describe a 54-year-old man with resistant pemphigus vulgaris. Standard therapies had afforded inadequate control and have been associated with considerable side-effects. The anti-CD20 monoclonal antibody, Rituximab (MabThera, Roche), was trialled with significant benefit. We discuss its potential mechanism of action.
- Subjects :
- Antibodies, Monoclonal, Murine-Derived
Biopsy
Fluorescent Antibody Technique
Humans
Male
Middle Aged
Pemphigus diagnosis
Prednisolone administration & dosage
Rituximab
Treatment Outcome
Antibodies, Monoclonal administration & dosage
Dermatologic Agents administration & dosage
Pemphigus drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0307-6938
- Volume :
- 28
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Clinical and experimental dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 12823293
- Full Text :
- https://doi.org/10.1046/j.1365-2230.2003.01283.x